OTCBB ALERTS

[Mandroid]

GenoMed GMED),a Next Generation Disease Management company whose business is public
health(TM), announced today that its CEO, David W. Moskowitz MD, was awarded
the 2006 Defender of Patient Safety Award in the physician category for
reversing chronic kidney failure from diabetes and high blood pressure. These
two diseases cause 90% of dialysis. The only alternative to dialysis is a
kidney transplant.
(Pink Sheets: The nation is in the middle of a dialysis epidemic. There were 200,000
dialysis patients in 2000. By 2010, there will be 300,000 patients on
dialysis. The average dialysis patient now costs Medicare $100,000 a year.
The average life expectancy on dialysis is only three years. Only 25,000
kidney transplants are performed each year, because there is a chronic
shortage of kidneys.
The number of dialysis patients is expected to swell even faster once the
Baby Boomers hit the age of 60.
Reversing chronic kidney failure means that dialysis could be prevented
altogether. But public awareness is key, since reversing kidney failure was
only possible early in the disease, before a patient's serum creatinine had
reached two (2). Serum creatinine is used to measure a person's kidney
function. The normal value is one (1); patients go on dialysis when it nears
ten (10).
Dr. Moskowitz's results were published in Diabetes Technology and
Therapeutics, a peer-reviewed medical journal, in September, 2002. If applied
nationally, Dr. Moskowitz's method could prevent up to 90% of dialysis, and
save Medicare over $22 billion a year. GenoMed owns the patents pending for
this novel treatment approach.
About Missouri Watch
Missouri Watch is the State of Missouri's leading patient and worker
safety advocacy coalition headquartered in Jefferson City.
http://www.missouriwatch.org
About GenoMed
GenoMed uses genomics to serve medicine(TM). The company's primary
commitment is to public health, including education. http://www.genomed.com
Safe Harbor Statement
This press release contains forward-looking statements, including those
statements pertaining to GenoMed, Inc.'s (the Company's) treatments. The
words or phrases "ought to," "should," "could," "may," or similar expressions
are intended to identify "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Actual results could
differ materially from those projected in the forward-looking statements as a
result of a number of risks and uncertainties, including but not limited to
our research and development being subject to scientific, economic,
regulatory, governmental, and technological factors. Statements made herein
are as of the date of this press release and should not be relied upon as of
any subsequent date. Unless otherwise required by applicable law, we
specifically disclaim any obligation to update any forward-looking statements
to reflect occurrences, developments, unanticipated events or circumstances
after the date of such statement.
SOURCE GenoMed, Inc.


Contact Information:
Ashley Allen, Executive Director of Missouri Watch, Inc., [phone], or David W. Moskowitz MD, CEO of GenoMed, [phone], [e-mail]

WebSite:
http://www.missouriwatch.org